Arrowhead Pharmaceuticals (ARWR) Capital Expenditures (2011 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 16 years of Capital Expenditures data on file, last reported at $2.6 million in Q1 2026.

• Quarterly Capital Expenditures fell 74.95% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.8 million (down 115.18% YoY) and the FY2025 annual result came in at $277000.0, down 99.8% from the prior year.
• Capital Expenditures advanced to $2.6 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $161.1 million in Q3 2023 to a low of -$50.6 million in Q2 2023.
• A 5-year average of $21.8 million and a median of $10.2 million in 2025 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures jumped 573.43% — and 2023, when it tumbled 630.63%.
• Tracing ARWR's Capital Expenditures over 5 years: stood at $38.9 million in 2022, then jumped by 76.44% to $68.7 million in 2023, then tumbled by 96.25% to $2.6 million in 2024, then retreated by 16.55% to $2.1 million in 2025, then increased by 19.41% to $2.6 million in 2026.
• The last three Capital Expenditures figures came in at $2.6 million (Q1 2026), $2.1 million (Q4 2025), and -$69000.0 (Q3 2025), per Business Quant data.